What is the likely diagnosis for a patient with recurrent erythematous rash, high fever, markedly elevated erythrocyte sedimentation rate and C-reactive protein, and a strong family history of identical episodes?

Hereditary Recurrent Fever (Autoinflammatory Disease)

This clinical presentation—recurrent erythematous rash, high fever, elevated ESR and CRP, plus a strong family history of identical symptoms—is highly suggestive of a hereditary recurrent fever (HRF) syndrome, most likely Familial Mediterranean Fever (FMF) if the patient has Mediterranean or Middle Eastern ancestry, or possibly TRAPS, CAPS, or mevalonate kinase deficiency (MKD) depending on specific clinical features.

Diagnostic Approach

The combination of recurrent inflammatory episodes with marked acute phase reactant elevation and familial clustering points directly to monogenic autoinflammatory diseases 1. These conditions result from pathogenic variants in genes regulating innate immunity, primarily affecting proinflammatory cytokine pathways 1.

Key Differential Diagnoses to Consider:

Recessive inheritance patterns:

• Familial Mediterranean Fever (FMF): Most common HRF, particularly in Mediterranean and Middle Eastern populations; caused by MEFV gene mutations 1
• Mevalonate Kinase Deficiency (MKD/HIDS): Caused by MVK gene mutations; episodes typically every 4-6 weeks 1

Dominant inheritance patterns:

• TNF Receptor-Associated Periodic Syndrome (TRAPS): TNFRSF1A gene mutations; episodes lasting ≥7 days with migratory rash 1, 2
• Cryopyrin-Associated Periodic Syndrome (CAPS): NLRP3 gene mutations 1

Clinical Features to Elicit:

• Episode duration: FMF attacks typically last 1-3 days; TRAPS >7 days; MKD 3-7 days
• Attack frequency: Document average attacks per month over 3-month period (critical for treatment decisions) 3
• Specific symptoms: Abdominal pain/peritonitis, pleuritis, arthritis, characteristic rash patterns
• Ethnicity/ancestry: FMF is more common in Mediterranean, Middle Eastern, Armenian, Turkish, Arab, and Sephardic Jewish populations 1
• Age of onset: Most HRFs begin in childhood
• Family pedigree: Recessive vs. dominant inheritance pattern

Diagnostic Testing

Proceed with genetic testing for HRF-responsible genes 1. Given overlapping clinical presentations, screening multiple genes simultaneously is often necessary when symptoms are atypical 1.

Required clinical data for genetic testing:

• Frequency and duration of attacks
• Sites affected (abdomen, joints, chest, skin)
• Acute phase reactant levels during and between attacks
• Family history details 1

Laboratory monitoring:

• CRP and ESR during attacks and between episodes (persistent subclinical inflammation indicates inadequate control) 3
• Serum amyloid A (SAA) for amyloidosis risk
• Urinalysis for renal function monitoring 1

Important Caveat:

Do not over-rely on genetic results alone. Diagnosis ultimately relies on clinical judgment even with genetic testing 1. A negative genetic test does not exclude HRF—rare undetected variants may exist, and not all pathogenic mutations are identified by standard panels 1. Conversely, finding a variant of uncertain significance requires clinical correlation and possibly parental testing to determine pathogenicity 1.

Treatment Algorithm

First-Line Treatment: Colchicine

Start colchicine immediately based on clinical suspicion 3:

• Adults: Start 1.0-1.5 mg/day, maximum 3 mg/day
• Children >10 years: 1.0-1.5 mg/day (1.8 mg if 0.6 mg tablets)
• Children 5-10 years: 0.5-1.0 mg/day
• Children <5 years: ≤0.5 mg/day

Titrate gradually (no more frequently than weekly) to reach target dose 3.

Monitoring Response

Assess every 3-6 months for:

• Clinical attack frequency
• Subclinical inflammation (CRP, ESR, SAA between attacks)
• Medication adherence 3

Defining Treatment Failure

Colchicine resistance = recurrent attacks (≥1 attack/month over 3 months) OR persistent laboratory inflammation between attacks despite maximum tolerated colchicine dose 3.

Second-Line: Biologic DMARDs

For colchicine-resistant or intolerant patients, add IL-1 inhibitors (highest evidence level) 3:

Preferred options:

• Anakinra: 100 mg/day or 2 mg/kg subcutaneously daily
• Canakinumab: 150-300 mg or 2-4 mg/kg subcutaneously every 4-8 weeks (strongest RCT evidence with 4 trials) 3
• Rilonacept: 2.2 mg/kg (max 160 mg) weekly subcutaneously

Alternative biologics (less evidence, require expert consultation):

• Tocilizumab (anti-IL-6): 162 mg or 4-8 mg/kg weekly subcutaneously
• Tofacitinib: 5 mg twice daily orally 3

Treatment Monitoring and Adjustment

• Regular visits every 3 months on biologics
• After 6-12 months of clinical and biochemical remission, consider tapering by decreasing dose OR increasing dose intervals 3
• If remission not achieved, increase biologic dose

Critical Pitfalls to Avoid

1. Don't dismiss the diagnosis if genetic testing is negative or shows only one variant in a recessive disease gene—clinical diagnosis takes precedence 1

2. Don't confuse with infectious causes: One case report describes recurrent erysipelas misdiagnosed as autoinflammatory disease despite positive NLRP3 mutation 4—always exclude infection

3. Don't ignore persistent subclinical inflammation between attacks—this indicates inadequate disease control and increases amyloidosis risk 3

4. Don't use intravenous colchicine—it is discouraged 3

5. Monitor for amyloidosis: The primary life-threatening complication is systemic AA amyloidosis with renal involvement 5. Regular urinalysis and renal function monitoring are essential 1

6. Chronic musculoskeletal involvement (spondyloarthropathy) may require additional conventional or biologic DMARDs beyond colchicine and IL-1 inhibitors 3